Fiche publication
Date publication
août 2017
Journal
Stem cells (Dayton, Ohio)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
,
Dr REPPEL Loïc
Tous les auteurs :
Laroye C, Gibot S, Reppel L, Bensoussan D
Lien Pubmed
Résumé
Sepsis and septic shock are the leading cause of admission and mortality in non-coronary intensive care units. Currently however no specific treatments are available for this syndrome. Due to the failure of conventional treatments, in recent years research is focussing on innovative therapeutic agents, including cell therapy. One particular type of cells, Mesenchymal Stromal/Stem Cells (MSCs), has raised hopes for the treatment of sepsis. Indeed, their immunomodulatory properties, antimicrobial activity and capacity of protection against organ failure confer MSCs with a major advantage to treat the immune and inflammatory dysfunctions associated with sepsis and septic shock. After a brief description of the pathophysiology of sepsis and septic shock, the latest advances in the use of MSCs to treat sepsis will be presented. This article is protected by copyright. All rights reserved.
Mots clés
Immunomodulation, Mesenchymal stromal/stem cells, Organs failures, Sepsis and septic shock, Treatment
Référence
Stem Cells. 2017 Aug;:
